Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corcept Therapeutics 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 USA

www.corcept.com P: 650-327-3270

Description:

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Key Statistics

Overview:

Market Capitalization, $K 2,393,909
Enterprise Value, $K 2,258,359
Shares Outstanding, K 104,083
Annual Sales, $ 482,380 K
Annual Net Income, $ 106,140 K
Last Quarter Sales, $ 135,410 K
Last Quarter Net Income, $ 31,360 K
EBIT, $ 107,280 K
EBITDA, $ 100,510 K
60-Month Beta 0.48
% of Insider Shareholders 19.80%
% of Institutional Shareholders 93.61%
Float, K 83,475
% Float 80.20%
Short Volume Ratio 0.83

Growth:

1-Year Return -0.09%
3-Year Return -1.36%
5-Year Return 77.99%
5-Year Revenue Growth 91.99%
5-Year Earnings Growth 56.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.28 on 02/15/24
Latest Earnings Date 05/01/24
Earnings Per Share ttm 0.95
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CORT Ratios

Ratio
Price/Earnings ttm 23.47
Price/Earnings forward 25.06
Price/Earnings to Growth N/A
Return-on-Equity % 21.98%
Return-on-Assets % 17.89%
Profit Margin % 22.00%
Debt/Equity 0.00
Price/Sales 4.81
Price/Cash Flow 23.96
Price/Book 4.67
Book Value/Share 4.92
Interest Coverage -1.68
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar